Investor Presentation
Filed with ASX · · 25 pages · English
Disclaimer This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange Limited (“ASX”). This presentation contains statements that involve estimates, risks and uncertainti
Genetic Signatures Ltd. on 6ix
In the deck
Story so far
Earlier from Genetic Signatures
- Update to major customer contract announcement
- Major Customer Contract Signed, New Kit and Instrument
- TGA registration for superbug detection kits
- Positive Trial Results Presented at ECCMID
- Appendix 4D and Half Year Financial Statements
Later from Genetic Signatures
- Additional Tax Incentive from understatement FY17 R&D Claim
- Appendix 4E and 2018 Financial Report
- Chairmans Address to Shareholders
- $2.6m R&D refund received
- CE-IVD Mark for Respiratory Pathogen Detection Kit
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures